MedTrace Logo

PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

NCT01441414 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2019-01-08

Study results available
· View outcomes & findings →

Summary

To evaluate the combination of PF-04856884 (CVX-060) in combination with Axitinib (AG-013736) in patients that have received one prior systemic regimen for metastatic renal cell carcinoma (mRCC) vs. axitinib alone.

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

BIOLOGICAL

PF-04856884

15 mg/kg/week intravenously \[IV\] until toxicity or disease progression

DRUG

Axitinib (AG-013736)

5 mg PO BID

DRUG

Axitinib (AG-013736)

5 mg PO BID

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-21
Primary Completion
2014-03-27
Completion
2014-03-27

Countries

  • United States
  • Czechia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01441414 on ClinicalTrials.gov